Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01324921 · ClinicalTrials.gov registry record · Phase 2

Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics

A Phase 2 study, sponsored by Abbott Nutrition.

Completed
Registry status
Phase 2
Development phase
37
Enrollment target

NCT01324921: Completed Phase 2 study, sponsored by Abbott Nutrition.

NCT01324921 is a Phase 2 study that has completed, run by Abbott Nutrition. The registered enrollment target is 37 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01324921, a Phase 2 study, has completed, sponsored by Abbott Nutrition.

COMPLETED
Registry status
Phase 2
Development phase
37 participants
Enrollment target

Study Summary

To compare the postprandial glycemic and insulinemic response of subjects with type 2 diabetes consuming a typical breakfast meal or no breakfast to 10004RF via a meal tolerance test (MTT).

Interventions

  • OTHER No breakfast/beverage only
  • OTHER Breakfast
  • OTHER 10004RF

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2010-08
Est. Completion 2010-09
Phase Phase 2
Abbott Nutrition

89 total trials

What the finished NCT01324921 record still lists

NCT01324921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 3 interventions - of which No breakfast/beverage only is the first listed.

NCT01324921 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01324921 about?

NCT01324921 is a clinical study titled "Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics". To compare the postprandial glycemic and insulinemic response of subjects with type 2 diabetes consuming a typical breakfast meal or no breakfast to 10004RF via a meal tolerance test (MTT).

What is the current status of trial NCT01324921?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2010-08. Estimated completion is 2010-09.

What interventions are being tested in trial NCT01324921?

The interventions under investigation include: No breakfast/beverage only (OTHER), Breakfast (OTHER), 10004RF (OTHER).

Who is sponsoring clinical trial NCT01324921?

This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01324921's enrollment target sits among peer trials

37 1484th of 2000 higher than 505 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01324921, the US trial registry maintained by the National Library of Medicine. NCT01324921 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.